\n \nDescription: \n \nDophylin (Doxophylline) is a novel bronchodilator. It structurally differs from Theophylline due to the presence of a dioxolane group in position 7. Doxophylline selectively inhibits phosphodiesterase-4 thereby relaxes bronchial smooth muscle. However, differently from Theophylline, Doxophylline appears to have decreased affinities toward adenosine A₁?and A₂?receptors, which may account for the better safety profile of the drug. Doxophylline is reported to inhibit platelet activating factor (PAF) and generation of leukotriene production. \n \n  \n \nComposition: \n \nEach film-coated tablet contains Doxophylline INN 400 mg. \n \n  \n \nIndication:? \n \nDophylin (Doxophylline) is used to treat asthma, COPD and?? bronchospasm. \n \n  \n \nDosage & Administration: \n \nAdults : 1 tablet daily at night. On the basis of clinical response the dose may be? increased to 1 tablet twice daily. \n \nChildren (above 6 years of age) : 6 mg/kg twice daily. \n \nOR AS DIRECTED BY THE PHYSICIAN. \n \n